source
- AtaiBeckley secured co-development and royalty offers before $2.8 B Lilly acquisitionAtaiBeckley, a psychedelic biotech, received co-development and royalty proposals prior to finalizing a $2.8 B acquisition by Eli Lilly. Details were disclosed in an SEC filing that outlined the s…
- Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programsSanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter. The bulk of the charge stems from the decision to terminate development of an eczema trea…